Caffeine regulates alternative splicing in a subset of cancer-associated genes: A role for SC35

Molecular and Cellular Biology

Volumn 28, Issue 2, 2008, Pages 883-895

  Shi, Jia ^a   Hu, Zhen ^a   Pabon, Kirk ^a   Scotto, Kathleen W ^a,b  

^a ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^b RUTGERS CANCER INSTITUTE OF NEW JERSEY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAFFEINE; CIS ACTING ELEMENT; COMPLEMENTARY DNA; KRUPPEL LIKE FACTOR 6; MESSENGER RNA PRECURSOR; PHOSPHORUS 32; RNA; RNA BINDING PROTEIN; SMALL INTERFERING RNA; SR PROTEIN SC35; UNCLASSIFIED DRUG;

ALTERNATIVE RNA SPLICING; ANIMAL CELL; ARTICLE; CANCER CELL CULTURE; CELL STRAIN HCT116; CONTROLLED STUDY; DIETARY INTAKE; ERYTHROLEUKEMIA CELL; FETUS; FIBROBLAST CULTURE; GLIOMA CELL; HELA CELL; HUMAN; HUMAN CELL; ISOTOPE LABELING; MELANOMA CELL; MICROARRAY ANALYSIS; MOUSE; NEOPLASM; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; RAT; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA INTERFERENCE; RNA PROBE; TUMOR SUPPRESSOR GENE; WESTERN BLOTTING;

ALTERNATIVE SPLICING; ANIMALS; BASE SEQUENCE; CAFFEINE; CELL LINE, TUMOR; EXONS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KRUPPEL-LIKE TRANSCRIPTION FACTORS; MOLECULAR SEQUENCE DATA; NEOPLASM PROTEINS; NUCLEAR PROTEINS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROTEIN ISOFORMS; PROTO-ONCOGENE PROTEINS; RIBONUCLEOPROTEINS;

EID: 37849029826     PISSN: 02707306     EISSN: None     Source Type: Journal    
DOI: 10.1128/MCB.01345-07     Document Type: Article

References (58)

1. Brinkman, B. M. 2004. Splice variants as cancer biomarkers. Clin. Biochem. 37:584-594.
2. Caceres, J. F., T. Misteli, G. R. Screaton, D. L. Spector, and A. R. Krainer. 1997. Role of the modular domains of SR proteins in subnuclear localization and alternative splicing specificity. J. Cell Biol. 138:225-238.
3. Caputi, M., and A. M. Zahler. 2002. SR proteins and hnRNP H regulate the splicing of the HIV-1 tev-specific exon 6D. EMBO J. 21:845-855.
4. Carter, M. S., J. Doskow, P. Morris, S. Li, R. P. Nhim, S. Sandstedt, and M. F. Wilkinson. 1995. A regulatory mechanism that detects premature nonsense codons in T-cell receptor transcripts in vivo is reversed by protein synthesis inhibitors in vitro. J. Biol. Chem. 270:28995-29003.
5. Cho, Y. G., B. J. Choi, J. W. Song, S. Y. Kim, S. W. Nam, S. H. Lee, N. J. Yoo, J. Y. Lee, and W. S. Park. 2006. Aberrant expression of krÜppel-like factor 6 protein in colorectal cancers. World J. Gastroenterol. 12:2250-2253.
6. Chou, M. Y., N. Rooke, C. W. Turck, and D. L. Black. 1999. hnRNP H is a component of a splicing enhancer complex that activates a c-src alternative exon in neuronal cells. Mol. Cell. Biol. 19:69-77.
7. Dominski, Z., and R. Kole. 1991. Selection of splice sites in pre-mRNAs with short internal exons. Mol. Cell. Biol. 11:6075-6083.
8. Ebbinghaus, C., J. Scheuermann, D. Neri, and G. Elia. 2004. Diagnostic and therapeutic applications of recombinant antibodies: targeting the extra-domain B of fibronectin, a marker of tumor angiogenesis. Curr. Pharm. Des. 10:1537-1549.
9. Eperon, I. C., O. V. Makarova, A. Mayeda, S. H. Munroe, J. F. Caceres, D. G. Hayward, and A. R. Krainer. 2000. Selection of alternative 5′ splice sites: role of U1 snRNP and models for the antagonistic effects of SF2/ASF and hnRNP A1. Mol. Cell. Biol. 20:8303-8318.
10. Fairbrother, W. G., and L. A. Chasin. 2000. Human genomic sequences that inhibit splicing. Mol. Cell. Biol. 20:6816-6825.
11. Fischer, D. C., K. Noack, I. B. Runnebaum, D. O. Watermann, D. G. Kieback, S. Stamm, and E. Stickeler. 2004. Expression of splicing factors in human ovarian cancer. Oncol. Rep. 11:1085-1090.
12. Fu, X. D., and T. Maniatis. 1990. Factor required for mammalian spliceosome assembly is localized to discrete regions in the nucleus. Nature 343:437-441.
13. Fu, X. D., A. Mayeda, T. Maniatis, and A. R. Krainer. 1992. General splicing factors SF2 and SC35 have equivalent activities in vitro, and both affect alternative 5′ and 3′ splice site selection. Proc. Natl. Acad. Sci. USA 89:11224-11228.
14. Graveley, B. R. 2000. Sorting out the complexity of SR protein functions. RNA 6:1197-1211.
15. Hanamura, A., J. F. Caceres, A. Mayeda, B. R. Franza, Jr., and A. R. Krainer. 1998. Regulated tissue-specific expression of antagonistic pre-mRNA splicing factors. RNA 4:430-444.
16. Hui, J., L. H. Hung, M. Heiner, S. Schreiner, N. Neumuller, G. Reither, S. A. Haas, and A. Bindereif. 2005. Intronic CA-repeat and CA-rich elements: a new class of regulators of mammalian alternative splicing. EMBO J. 24:1988-1998.
17. Hui, L., X. Zhang, X. Wu, Z. Lin, Q. Wang, Y. Li, and G. Hu. 2004. Identification of alternatively spliced mRNA variants related to cancers by genome-wide ESTs alignment. Oncogene 23:3013-3023.
18. Ibrahim E. C., T. D. Schaal, K. J. Hertel, R. Reed, and T. Maniatis. 2005. Serine/arginine-rich protein-dependent suppression of exon skipping by exonic splicing enhancers. Proc. Natl. Acad. Sci. USA 102:5002-5007.
19. Ito, G., M. Uchiyama, M. Kondo, S. Mori, N. Usami, O. Maeda, T. Kawabe, Y. Hasegawa, K. Shimokata, and Y. Sekido. 2004. Kruppel-like factor 6 is frequently down-regulated and induces apoptosis in non-small cell lung cancer cells. Cancer Res. 64:3838-3843.
20. Jeng, Y. M., and H. C. Hsu. 2003. KLF6, a putative tumor suppressor gene, is mutated in astrocytic gliomas. Int. J. Cancer 105:625-629.
21. Jin, S., and K. W. Scotto. 1998. Transcriptional regulation of the MDR1 gene by histone acetyltransferase and deacetylase is mediated by NF-Y. Mol. Cell. Biol. 18:4377-4384.
22. Kalnina, Z., P. Zayakin, K. Silina, and A. Line. 2005. Alterations of pre-mRNA splicing in cancer. Genes Chromosomes Cancer 42:342-357.
23. Karni, R., E. de Stanchina, S. W. Lowe, R. Sinha, D. Mu, and A. R. Krainer. 2007. The gene encoding the splicing factor SF2/ASF is a proto-oncogene. Nat. Struct. Mol. Biol. 14:185-193.
24. Kessler, K. R., and R. Benecke. 1997. The EBD test: a clinical test for the detection of antibodies to botulinum toxin type A. Mov. Disord. 12:95-99.
25. Kim, S., H. Shi, D. K. Lee, and J. T. Lis. 2003. Specific SR protein-dependent splicing substrates identified through genomic SELEX. Nucleic Acids Res. 31:1955-1961.
26. Kimmelman, A. C., R. F. Qiao, G. Narla, A. Banno, N. Lau, P. D. Bos, N. Nunez Rodriguez, B. C. Liang, A. Guha, J. A. Martignetti, S. L. Friedman, and A. M. Chan. 2004. Suppression of glioblastoma tumorigenicity by the Kruppel-like transcription factor KLF6. Oncogene 23:5077-5083.
27. Kirschbaum-Slager, N., G. M. Lopes, P. A. Galante, G. J. Riggins, and S. J. de Souza. 2004. Splicing factors are differentially expressed in tumors. Genet. Mol. Res. 3:512-520.
28. Lin, S., R. Xiao, P. Sun, X. Xu, and X. D. Fu. 2005. Dephosphorylation-dependent sorting of SR splicing factors during mRNP maturation. Mol. Cell 20:413-425.
29. Liu, H. X., S. L. Chew, L. Cartegni, M. Q. Zhang, and A. R. Krainer. 2000. Exonic splicing enhancer motif recognized by human SC35 under splicing conditions. Mol. Cell. Biol. 20:1063-1071.
30. Maeda, T., and S. Furukawa. 2001. Transformation-associated changes in gene expression of alternative splicing regulatory factors in mouse fibroblast cells. Oncol. Rep. 8:563-566.
31. Manley, J. L., and R. Tacke. 1996. SR proteins and splicing control. Genes Dev. 10:1569-1579.
32. Matlin, A. J., F. Clark, and C. W. Smith. 2005. Understanding alternative splicing: towards a cellular code. Nat. Rev. Mol. Cell Biol. 6:386-398.
33. Mayeda, A., S. H. Munroe, J. F. Caceres, and A. R. Krainer. 1994. Function of conserved domains of hnRNP A1 and other hnRNP A/B proteins. EMBO J. 13:5483-5495.
34. Modafferi, E. F., and D. L. Black. 1997. A complex intronic splicing enhancer from the c-src pre-mRNA activates inclusion of a heterologous exon. Mol. Cell. Biol. 17:6537-6545.
35. Modrek, B., and C. J. Lee. 2003. Alternative splicing in the human, mouse and rat genomes is associated with an increased frequency of exon creation and/or loss. Nat. Genet. 34:177-180.
36. Modrek, B., A. Resch, C. Grasso, and C. Lee. 2001. Genome-wide detection of alternative splicing in expressed sequences of human genes. Nucleic Acids Res. 29:2850-2859.
37. Nagy, E., and L. E. Maquat. 1998. A rule for termination-codon position within intron-containing genes: when nonsense affects RNA abundance. Trends Biochem. Sci. 23:198-199.
38. Narla, G., A. Difeo, H. L. Reeves, D. J. Schaid, J. Hirshfeld, E. Hod, A. Katz, W. B. Isaacs, S. Hebbring, A. Komiya, S. K. McDonnell, K. E. Wiley, S. J. Jacobsen, S. D. Isaacs, P. C. Walsh, S. L. Zheng, B. L. Chang, D. M. Friedrichsen, J. L. Stanford, E. A. Ostrander, A. M. Chinnaiyan, M. A. Rubin, J. Xu, S. N. Thibodeau, S. L. Friedman, and J. A. Martignetti. 2005. A germline DNA polymorphism enhances alternative splicing of the KLF6 tumor suppressor gene and is associated with increased prostate cancer risk. Cancer Res. 65:1213-1222.
39. Narla, G., A. DiFeo, S. Yao, A. Banno, E. Hod, H. L. Reeves, R. F. Qiao, O. Camacho-Vanegas, A. Levine, A. Kirschenbaum, A. M. Chan, S. L. Friedman, and J. A. Martignetti. 2005. Targeted inhibition of the KLF6 splice variant, KLF6 SV1, suppresses prostate cancer cell growth and spread. Cancer Res. 65:5761-5768.
40. Narla, G., K. E. Heath, H. L. Reeves, D. Li, L. E. Giono, A. C. Kimmelman, M. J. Glucksman, J. Narla, F. J. Eng, A. M. Chan, A. C. Ferrari, J. A. Martignetti, and S. L. Friedman. 2001. KLF6, a candidate tumor suppressor gene mutated in prostate cancer. Science 294:2563-2566.
41. Narla, G., S. Kremer-Tal, N. Matsumoto, X. Zhao, S. Yao, K. Kelley, M. Tarocchi, and S. L. Friedman. 2007. In vivo regulation of p21 by the Kruppel-like factor 6 tumor-suppressor gene in mouse liver and human hepatocellular carcinoma. Oncogene 26:4428-4434.
42. Noonan, K. E., C. Beck, T. A. Holzmayer, J. E. Chin, J. S. Wunder, I. L. Andrulis, A. F. Gazdar, C. L. Willman, B. Griffith, D. D. Von Hoff, et al. 1990. Quantitative analysis of MDR1 (multidrug resistance) gene expression in human tumors by polymerase chain reaction. Proc. Natl. Acad. Sci. USA 87:7160-7164.
43. Ohler, U., N. Shomron, and C. B. Burge. 2005. Recognition of unknown conserved alternatively spliced exons. PLoS Comput. Biol. 1:113-122.
44. Pan, X. C., Z. Chen, F. Chen, X. H. Chen, C. Zhou, and Z. G. Yang. 2006. Mutations of the tumor suppressor Kruppel-like factor 6 (KLF6) gene in hepatocellular carcinoma and its effect of growth suppression on human hepatocellular carcinoma cell line HepG2. Zhonghua Gan Zang Bing Za Zhi 14:109-113. (In Chinese.)
45. Reeves, H. L., G. Narla, O. Ogunbiyi, A. I. Haq, A. Katz, S. Benzeno, E. Hod, N. Harpaz, S. Goldberg, S. Tal-Kremer, F. J. Eng, M. J. Arthur, J. A. Martignetti, and S. L. Friedman. 2004. Kruppel-like factor 6 (KLF6) is a tumor-suppressor gene frequently inactivated in colorectal cancer. Gastroenterology 126:1090-1103.
46. Sadusky, T., A. J. Newman, and N. J. Dibb. 2004. Exon junction sequences as cryptic splice sites: implications for intron origin. Curr. Biol. 14:505-509.
47. Smid-Koopman, E., L. J. Blok, T. J. Helmerhorst, S. Chadha-Ajwani, C. W. Burger, A. O. Brinkmann, and F. J. Huikeshoven. 2004. Gene expression profiling in human endometrial cancer tissue samples: utility and diagnostic value. Gynecol. Oncol. 93:292-300.
48. Spellman, R., A. Rideau, A. Matlin, C. Gooding, F. Robinson, N. McGlincy, S. N. Grellscheid, J. Southby, M. Wollerton, and C. W. Smith. 2005. Regulation of alternative splicing by PTB and associated factors. Biochem. Soc. Trans. 33:457-460.
49. Tacke, R., and J. L. Manley. 1995. The human splicing factors ASF/SF2 and SC35 possess distinct, functionally significant RNA binding specificities. EMBO J. 14:3540-3551.
50. Usuki, F., A. Yamashita, I. Higuchi, T. Ohnishi, T. Shiraishi, M. Osame, and S. Ohno. 2004. Inhibition of nonsense-mediated mRNA decay rescues the phenotype in Ullrich's disease. Ann. Neurol. 55:740-744.
51. Venables, J. P. 2004. Aberrant and alternative splicing in cancer. Cancer Res. 64:7647-7654.
52. Venables, J. P. 2006. Unbalanced alternative splicing and its significance in cancer. Bioessays 28:378-386.
53. Wang, Z., H. S. Lo, H. Yang, S. Gere, Y. Hu, K. H. Buetow, and M. P. Lee. 2003. Computational analysis and experimental validation of tumor-associated alternative RNA splicing in human cancer. Cancer Res. 63:655-657.
54. Wang, Z., M. E. Rolish, G. Yeo, V. Tung, M. Mawson, and C. B. Burge. 2004. Systematic identification and analysis of exonic splicing silencers. Cell 119:831-845.
55. Wang, Z., X. Xiao, E. Van Nostrand, and C. B. Burge. 2006. General and specific functions of exonic splicing silencers in splicing control. Mol. Cell 23:61-70.
56. Watakabe, A., K. Tanaka, and Y. Shimura. 1993. The role of exon sequences in splice site selection. Genes Dev. 7:407-418.
57. Xu, Q., and C. Lee. 2003. Discovery of novel splice forms and functional analysis of cancer-specific alternative splicing in human expressed sequences. Nucleic Acids Res. 31:5635-5643.
58. Zhu, J., A. Mayeda, and A. R. Krainer. 2001. Exon identity established through differential antagonism between exonic splicing silencer-bound hnRNP A1 and enhancer-bound SR proteins. Mol. Cell 8:1351-1361.